CoChat

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

Emerging evidence supports a key role for the gut microbiota in metabolic diseases, including type 2 diabetes (T2D) and obesity. The dipeptidyl peptidase-4 inhibitor vildagliptin is highly efficacious in treating T2D. However, whether vildagliptin can alter the gut microbiome is still unclear. This study aimed to identify whether vildagliptin modifies the gut microbiota structure during T2D treatment. Diabetic Sprague-Dawley (SD) rats were induced by a high-fat diet and streptozotocin injection (HFD/STZ). Diabetic rats were orally administered a low dose of vildagliptin (LV, 0.01 g/kg/d vildagliptin), high dose of vildagliptin (HV, 0.02 g/kg/d vildagliptin), or normal saline for 12 weeks. Fasting blood glucose, blood glucose after glucose loading, and serum insulin levels were significantly reduced in the LV and HV groups compared with those in the T2D group. The serum GLP-1 level increased more in the vildagliptin-treated group than in the T2D group. Pyrosequencing of the V3-V4 regions of 16S rRNA genes revealed that vildagliptin significantly altered the gut microbiota. The operational taxonomic units (OTUs) and community richness (Chao1) index were significantly reduced in the vildagliptin and diabetic groups compared with those in the control group. At the phylum level, a higher relative abundance of Bacteroidetes, lower abundance of Firmicutes, and reduced ratio of Fimicutes/Bacteroidetes were observed in the vildagliptin-treated group. Moreover, vildagliptin treatment increased butyrate-producing bacteria, including Baceroides and Erysipelotrichaeae, in the diabetic rats. Moreover, Lachnospira abundance was significantly negatively correlated with fasting blood glucose levels. In conclusion, vildagliptin treatment could benefit the communities of the gut microbiota.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0184735

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Effect of vildagliptin treatment on body weight, blood glucose, HbA1c, serum insulin, HOMA-IR, GLP-1, and IL-6. (A) body weight, (B) fasting blood glucose, (C) HbA1c, (D) glucose tolerance, (E) area under the curve of blood glucose, (F) serum insulin, (G) HOMA-IR, (H) GLP-1, (I) IL-6. Data was represented as mean ± SD. n = 6 in each group. * P<0.05, ** P<0.01, NS not significant.
Fig 1 Effect of vildagliptin treatment on body weight, blood glucose, HbA1c, serum insulin, HOMA-IR, GLP-1, and IL-6. (A) body weight, (B) fasting blood glucose, (C) HbA1c, (D) glucose tolerance, (E) area under the curve of blood glucose, (F) serum insulin, (G) HOMA-IR, (H) GLP-1, (I) IL-6. Data was represented as mean ± SD. n = 6 in each group. * P<0.05, ** P<0.01, NS not significant.CC BY · PubMed Central
Fig 2 Pyrosequencing data summary. (A) number of OTUs, (B) Shannon index, and (C) Chao1 index. Data was represented as mean ± SD. n = 6 in each group. *P<0.05, ** P<0.01, NS not significant.
Fig 2 Pyrosequencing data summary. (A) number of OTUs, (B) Shannon index, and (C) Chao1 index. Data was represented as mean ± SD. n = 6 in each group. *P<0.05, ** P<0.01, NS not significant.CC BY · PubMed Central
Fig 3 PCoA plots of weighted UniFrac distances of fecal microbial communities.
Fig 3 PCoA plots of weighted UniFrac distances of fecal microbial communities.CC BY · PubMed Central
Fig 4 Shared OUT analysis of the different groups. Venn diagram showing the unique and shared OTUs (3% distance level) in the different groups.
Fig 4 Shared OUT analysis of the different groups. Venn diagram showing the unique and shared OTUs (3% distance level) in the different groups.CC BY · PubMed Central
Fig 5 Heat map of the relative abundance (log10 transformation) of specific taxa in the fecal microbiota of rats in phyla level.
Fig 5 Heat map of the relative abundance (log10 transformation) of specific taxa in the fecal microbiota of rats in phyla level.CC BY · PubMed Central
Fig 6 The LEfSe analysis of the gut microbiota in vildagliptin-treated rats differed significantly from that in NC and HFD/STZ group. (A) Differences are represented in the color of the most abundant group. (B) The left histogram shows the lineages with LDA values of 3.0 or higher as determined by LEfSe. The right heap map shows the relative abundance (log10 transformation) of OTUs.
Fig 6 The LEfSe analysis of the gut microbiota in vildagliptin-treated rats differed significantly from that in NC and HFD/STZ group. (A) Differences are represented in the color of the most abundant group. (B) The left histogram shows the lineages with LDA values of 3.0 or higher as determined by LEfSe. The right heap map shows the relative abundance (log10 transformation) of OTUs.CC BY · PubMed Central
Fig 7 Correlation of the gut microbiota with glucose metabolism index. The left heat map shows the correlation coefficients between the OTUs and various glucose metabolism parameters. The right heat map shows the relative abundance (log10 transformed) of OTUs in the different groups. n = 6 in each group. **P<0.01, *** P<0.001.
Fig 7 Correlation of the gut microbiota with glucose metabolism index. The left heat map shows the correlation coefficients between the OTUs and various glucose metabolism parameters. The right heat map shows the relative abundance (log10 transformed) of OTUs in the different groups. n = 6 in each group. **P<0.01, *** P<0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 124

Metadata

Authors
Zhang, Q., Xiao, X., Li, M., Yu, M., Ping, F., Zheng, J., Wang, T., & Wang, X.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Xiao, Xinhua
Venue
PLOS ONE
Published
2017-10-16
Volume
12
Issue
10
Pages
e0184735
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2765808908
Cited by
124
References
56
Citations by year
2026: 5 · 2025: 14 · 2024: 11 · 2023: 26 · 2022: 21 · 2021: 15 · 2020: 14 · 2019: 11 · 2018: 6
FWCI
3.46
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Key Research and Development Program of China (2016YFA0101002)
  • National Natural Science Foundation of China (81170736, 81570715)
  • National Natural Science Foundation for Young Scholars of China (81300649)
  • China Scholarship Council Foundation (201308110443)
  • PUMC Youth Fund (33320140022)
  • China Diabetes Young Scientific Talent Research Funding
  • Diabetes Research Fund from Clinical Research of Chinese Medical Association and Chinese Diabetes Society (12030500350)
  • Fundamental Research Funds for the Central Universities
  • the Scientific Activities Foundation for Selected Returned Overseas Professional of Human Resources and Social Security Ministry
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
vildagliptin, type 2 diabetes, gut microbiota, butyrate-producing bacteria, DPP-4 inhibitors, high-fat diet and streptozotocin-induced diabetes, glucagon-like peptide-1, Firmicutes/Bacteroidetes ratio, Bacteroides, Lachnospira, fasting blood glucose, insulin
MeSH terms
Gastrointestinal Microbiome, Vildagliptin, Adamantane, Administration, Oral, Animals, Blood Glucose, Butyrates, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Insulin Resistance, Male, Nitriles, Pyrrolidines, Random Allocation, RNA, Ribosomal, 16S, Interleukin-6, Rats, Sprague-Dawley, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. https://app.cochat.ai/papers/10.1371/journal.pone.0184735
The paper
Zhang, Q., Xiao, X., Li, M., Yu, M., Ping, F., Zheng, J., Wang, T., & Wang, X. (2017). Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLOS ONE. https://doi.org/10.1371/journal.pone.0184735

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.